<DOC>
	<DOCNO>NCT00196339</DOCNO>
	<brief_summary>This study compare efficacy safety 3 dose DR-2031 placebo use `` add-on '' therapy prostate cancer patient hot flash follow surgical medical castration . All prostate cancer therapy must stable least 45 day enter study must remain stable throughout 12-week study . Patients maintain daily paper diary record frequency severity hot flash treatment period .</brief_summary>
	<brief_title>A Clinical Trial Study DR-2031 Treatment Hot Flashes Prostate Cancer Patients</brief_title>
	<detailed_description>This study compare efficacy safety 3 dose DR-2031 placebo use `` add-on '' therapy prostate cancer patient mild moderate vasomotor symptom ( hot flash ) follow surgical medical castration . All prostate cancer therapy must stable least 45 day enter study must remain stable throughout 12-week study . To eligible study prostate cancer patient must undergo bilateral orchiectomy medical castration utilize LHRH analogue ( LHRH agonists LHRH antagonist ) without additional antiandrogen therapy . Patients must least 21 moderate severe hot flash weekly . Patients maintain daily paper diary record frequency severity hot flash treatment period . In addition , brief physical evaluation do , diary review adverse event record follow-up evaluation .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<criteria>Prostate cancer patient undergone chemical surgical castration History hot flash least 30 day Stable prostate cancer therapy least 45 day Uncontrolled diabetes severe COPD History thromboembolic disease Liver kidney dysfunction History presence cancer prostate cancer within last 5 year Surgery within last 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>hot flash</keyword>
	<keyword>hot flush</keyword>
	<keyword>vasomotor symptom</keyword>
</DOC>